Teva DuoResp® Spiromax® New-to-Therapy Patient Program

In July 2018, Kos designed, developed, and implemented the Teva DuoResp® Spiromax® New-to-Therapy Patient Program (Program) for Teva Pharma Australia Pty. Ltd. (Teva). The program partnered with Community Pharmacy to provide DuoResp Spiromax (budesonide/formoterol) is an inhaled medicine used to treat asthma and chronic obstructive pulmonary disease (COPD).